Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Michael Freeman is an analyst at Raymond James. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 04/05/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11/20/2024 | MDP | Buy Now | Medexus Pharma | — | — | Michael Freeman1% | $3 → $4 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/10/2024 | BHC | Buy Now | Bausch Health Companies | $5.50 | 45.45% | Michael Freeman1% | → $8 | Initiates | → Market Perform | Get Alert |
